RNA Therapeutic
Oct 01, 2026
UTR Therapeutics’ UTRxMYCN M1-14 Granted FDA Orphan Drug and Rare Pediatric Disease Designations; Medtronic Announces Regulatory Milestones for New Cardiac Mapping and Ablation Software; Abbott Adds SimpleScreen™ CRC Blood Test to Colorectal Cancer Screening Portfolio; VEMERIX Introduces Patented Single-Use Ultrasound Puncture Kit With Customized Probe Compatibility; Avisi Technologies to Showcase Two-Year VisiPlate® Results at AAO Annual Meeting; FIRE1 Implants First Patient in NORM-HF Pivotal Trial for Innovative Heart Failure Management
UTR Therapeutics Inc. Announced U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation for UTRxMYCN M1-14 On 29 September 2026, UTR Therapeutics Inc. announced that the U.S. FDA had granted Orphan Drug Designation to UTRxMYCN M1-14 for the treatment of soft tissue sarcoma, including rhabdomyosar...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
